Johnson Margaret E ME

Show results for

Unknown (14)
Metabolomics (2)
Transcriptomics (1)

Organisms

Homo sapiens (1)

Repository

MetaboLights (2)
biostudies-arrayexpress (1)

Technology Type

NMR spectroscopy (1)
Mass spectrometry (1)

Instrument Platform

Nuclear Magnetic Resonance (NMR) - (1)
Liquid Chromatography MS - negative - hilic (1)

Publication Date

2010 (1)
2024 (1)
2022 (1)

CHEBI ID

CHEBI:85210 (1)
CHEBI:24329 (1)
CHEBI:172431 (1)
CHEBI:15245 (1)
CHEBI:132966 (1)
CHEBI:46905 (1)
CHEBI:170015 (1)
CHEBI:47977 (1)
CHEBI:17786 (1)
CHEBI:139582 (1)
CHEBI:45826 (1)
CHEBI:35932 (1)
CHEBI:15729 (1)
CHEBI:18095 (1)
CHEBI:84058 (1)
CHEBI:18403 (1)
CHEBI:62324 (1)
CHEBI:16731 (1)
CHEBI:40992 (1)
CHEBI:40410 (1)
CHEBI:43355 (1)
CHEBI:27956 (1)
CHEBI:26806 (1)
CHEBI:16668 (1)
CHEBI:16977 (1)
CHEBI:14314 (1)
CHEBI:17775 (1)
CHEBI:16924 (1)
CHEBI:28478 (1)
CHEBI:18107 (1)

Metabolite Name

XANTHOSINE (1)
URIDINE-5-MONOPHOSPHATE (1)
TRANS-CINNAMATE (1)
TRANS-CINNAMALDEHYDE (1)
TRANS-4-HYDROXYPROLINE (1)
THYMINE (1)
THYMIDINE 5-MONOPHOSPHATE (1)
THYMIDINE (1)
TAURINE (1)
SUCROSE (1)
SHIKIMATE (1)
OMEGA-HYDROXYDODECANOIC ACID (1)
NICOTINATE (1)
N-METHYL-D-ASPARTIC ACID (1)
N-ALPHA-ACETYL-L-ASPARAGINE (1)
N-ACETYLGLYCINE (1)
N-acetyl-L-threonine (1)
N-ACETYL-L-PHENYLALANINE (1)
N-ACETYL-L-LEUCINE (1)
N-ACETYL-L-ASPARTIC ACID (1)
N-ACETYL-DL-GLUTAMIC ACID (1)
N-ACETYL-D-TRYPTOPHAN (1)
L-VALINE (1)
L-TYROSINE (1)
L-TRYPTOPHAN (1)
L-THREONINE (1)
L-SERINE (1)
L-PHENYLALANINE (1)
L-METHIONINE (1)
L-HISTIDINE (1)

Study type

Comparative genomic hybridization by array (1)

Release Date

2024 (3)
2023 (3)
2021 (2)
2010 (1)
2025 (1)
2022 (1)
2020 (1)
2019 (1)
2018 (1)
2012 (1)

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

Examining the Landscape of Prognostic Factors and Clinical Outcomes for Cancer Control.

Not available

S-EPMC8699872 | biostudies-literature

Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.

Not available

S-EPMC11897230 | biostudies-literature

Contribution of fungal microbiome to intestinal physiology, early-life immune development and mucosal inflammation in mice

The gut microbiome consists of a multi-kingdom microbial community. Whilst the role of bacteria as causal contributors governing host physiological development is well established, the role of fungi remains to be determined. Here, we use germ-free mice colonized with defined species of bacteria, fun...

2022-01-14 | MTBLS1679 | MetaboLights

A robust method for performing 1H-NMR lipidomics in embryonic zebrafish

The embryonic zebrafish is an ideal system for lipid analyses with relevance to many areas of bioscience research, including biomarkers and therapeutics. Research in this area has been hampered by difficulties in extracting, identifying and quantifying lipids. We employed 1H-NMR at 700MHz to profile...

2024-07-02 | MTBLS2396 | MetaboLights

BRCA1 frameshift variants leading to extended incorrect protein C termini.

Not available

S-EPMC10558845 | biostudies-literature

Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with ALT

Soft tissue sarcomas are a diverse set of fatal human tumors where few agents have demonstrable clinical efficacy, with the standard therapeutic combination of doxorubicin and ifosfamide showing only a 25-30% response rate in large multi-institutional trials. Although liposarcomas are the most commo...

ORGANISM(S): Homo sapiens

2010-03-03 | E-GEOD-19449 | biostudies-arrayexpress

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

Not available

S-EPMC6722042 | biostudies-literature

Divergent mutational processes distinguish hypoxic and normoxic tumours.

Not available

S-EPMC7002770 | biostudies-literature

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

Not available

S-EPMC5840256 | biostudies-literature

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.